Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Want to see PCRX full AI Analyst Report?
PCRX Stock Chart & Stats
$24.72
-$0.08(-0.43%)
At close: 4:00 PM EST
$24.72
-$0.08(-0.43%)
Day’s Range― - ―
52-Week Range$18.80 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)620.19K
Market Cap
$1.00B
Enterprise Value$1.38B
Total Cash (Recent Filing)$144.31M
Total Debt (Recent Filing)$9.82M
Price to Earnings (P/E)32.3
Beta0.84
Next Earnings
Aug 04, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.60
Shares Outstanding39,334,984
10 Day Avg. Volume434,058
30 Day Avg. Volume620,187
Financial Highlights & Ratios
PEG Ratio-1.53
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit3.12
Enterprise Value/Ebitda14.38
Forecast
1Y Price Target
$28.40Price Target Upside14.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.62
Revenue Forecast (FY)$759.71M
Bulls Say, Bears Say
Bulls Say
Capital Allocation And Analyst ConvictionAnalyst maintains a Buy rating while management outlines a clear multi-objective growth strategy and the company continues share repurchases, signaling potential upside not fully captured in the stock price.
Clinical EconomicsReal-world data show Exparel can reduce opioid use and produce lower or comparable total healthcare costs, supporting stronger clinical adoption and value-based positioning.
Commercial Access And ApprovalsExpanded payer coverage and nerve-block approvals combined with the NOPAIN initiative increase treatment access and can drive meaningful Exparel volume growth across key markets.
Bears Say
Competitive And Execution RiskPotential generic competition and the possibility that new growth initiatives or early-stage assets fail to deliver create material downside risk to the company’s outlook.
Pricing And Profitability PressureDiscounting tied to a group purchasing agreement and elevated selling and administrative expenses from litigation and business development activities are pressuring net pricing and profitability.
Reimbursement Risk In Knee ProceduresEconomic benefits for total knee arthroplasty lack strong statistical support, which weakens the case for broad reimbursement in a major procedure category.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $18.80 and its highest was $27.64 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $1.00B.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 94 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Apr 30, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of $0.548 by $0.052.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.66.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 39,334,984 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.6 in its last earnings report, beating expectations of $0.548. Following the earnings report the stock price went down -4.119%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.40 (14.89% Upside)
$28.40 (14.89% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 47.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.28%
12-Months-Change
Fundamentals
Return on Equity
0.95%
Trailing 12-Months
Asset Growth
-18.58%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominately positive picture: the company reported solid top-line momentum across core products (EXPAREL, ZILRETTA, ioverao) with meaningful YoY growth, strengthened IP protection, expanded reimbursement coverage (110M+ covered lives), encouraging pipeline progress with near-term readouts, and healthy adjusted EBITDA and buyback activity. Near-term challenges include revenue mix impacts from a new GPO and winter storms, modest margin compression and elevated SG&A/R&D spending tied to strategic initiatives, and policy timing risk around NOPAIN’s scheduled 2027 expiration. On balance the positives — sustainable product growth, strengthened commercial and IP positions, active pipeline catalysts, and disciplined capital returns — outweigh the lowlights.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$28.40
▲(14.89% Upside)
Technical Analysis
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
3.78% Insiders
25.84% Mutual Funds
3.79% Other Institutional Investors
33.35% Public Companies and
Individual Investors